Cover Image
市場調查報告書

纖維母細胞生長因子受體4:開發中產品分析

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 367825
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
纖維母細胞生長因子受體4:開發中產品分析 Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 103 Pages
簡介

本報告提供以纖維母細胞生長因子受體4為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

纖維母細胞生長因子受體4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Amgen Inc.
  • ArQule, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AVEO Pharmaceuticals, Inc.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • 第一三共
  • Eddingpharm
  • Eisai
  • Eli Lilly and Company
  • Genosco
  • H3 Biomedicine Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • NGM Biopharmaceuticals, Inc.
  • Novartis AG
  • Principia Biopharma Inc.
  • Vichem Chemie Research Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0812TDB

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Chronic Lymphocytic Leukemia (CLL), Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Nasopharyngeal Cancer, Non-Small Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview
    • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
    • Amgen Inc
    • ArQule Inc
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Blueprint Medicines Corp
    • Bristol-Myers Squibb Company
    • Eisai Co Ltd
    • Eli Lilly and Company
    • Genosco Inc
    • H3 Biomedicine Inc
    • Incyte Corp
    • Ionis Pharmaceuticals Inc
    • Johnson & Johnson
    • NGM Biopharmaceuticals Inc
    • Novartis AG
    • Principia Biopharma Inc
    • Tasly Pharmaceutical Group Co Ltd
    • Vichem Chemie Research Ltd
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles
    • ARQ-087 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5878 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-709 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLU-9931 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-986036 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erdafitinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ES-135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FGF-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • golvatinib tartrate + lenvatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • H-3B6527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-62079 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • infigratinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IONIS-463588 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lenvatinib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-2874455 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NGM-282 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRN-1371 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein 1 to Agonize Fibroblast Growth Factor Receptor for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TSLB-1344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products
  • Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 05, 2017: Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab for the Treatment of Endometrial Carcinoma at 53rd ASCO Annual Meeting
      • Jun 05, 2017: Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd Asco Annual Meeting
      • May 18, 2017: Eisai to Present Abstracts on Lenvatinib At 53rd ASCO Annual Meeting
      • May 17, 2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting
      • Apr 22, 2017: Bristol-Myers Squibb's BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
      • Apr 22, 2017: NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
      • Apr 05, 2017: Eisai Presents Data Of Mechanisms Of Action Relating To Tumor Immune Response Regarding Combination Of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody At AACR 108th Annual Meeting
      • Apr 05, 2017: NGM Bio to Present Phase 2 Data of NGM282 in NASH at International Liver Congress 2017
      • Mar 28, 2017: Eisai to Present Data on Lenvima at 2017 AACR Annual Meeting
      • Mar 28, 2017: German Federal Joint Committee (G-BA) Confirms Additional Benefit of Kisplyx (lenvatinib) in Treatment of Advanced Renal Cell Carcinoma
      • Mar 27, 2017: Blueprint Medicines to Present on BLU-554 at Upcoming Scientific Conferences
      • Mar 23, 2017: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug
      • Mar 09, 2017: H3 Biomedicine to Present on H3B-6527 at 2017 American Association of Cancer Research Annual Meeting
      • Jan 25, 2017: Phase III Trial Of Anticancer Agent Lenvima As First-Line Treatment For Unresectable Hepatocellular Carcinoma Meets Primary Endpoint
      • Jan 04, 2017: German Institute for Quality and Efficiency in Health Care Confirms Additional Benefit for Kisplyx (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Amgen Inc, H1 2017
  • Pipeline by ArQule Inc, H1 2017
  • Pipeline by Astellas Pharma Inc, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by Blueprint Medicines Corp, H1 2017
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by Eisai Co Ltd, H1 2017
  • Pipeline by Eli Lilly and Company, H1 2017
  • Pipeline by Genosco Inc, H1 2017
  • Pipeline by H3 Biomedicine Inc, H1 2017
  • Pipeline by Incyte Corp, H1 2017
  • Pipeline by Ionis Pharmaceuticals Inc, H1 2017
  • Pipeline by Johnson & Johnson, H1 2017
  • Pipeline by NGM Biopharmaceuticals Inc, H1 2017
  • Pipeline by Novartis AG, H1 2017
  • Pipeline by Principia Biopharma Inc, H1 2017
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Pipeline by Vichem Chemie Research Ltd, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top